Acadia Pharma Q4 Loss Widens, But Tops View; Revenues Miss - Quick Facts

(RTTNews) - Biopharmaceutical company Acadia Pharmaceuticals Inc. (ACAD) on Thursday reported fourth-quarter net loss of $12.05 million or $0.13 per share, wider than net loss of $6.81 million or $0.11 per share in the comparable quarter last year.

The net losses for the fourth quarters of 2013 and 2012 included non-cash, stock-based compensation expense of $2.2 million and $552,000, respectively. On average, six analysts polled by Thomson Reuters expected the company to report loss of $0.14 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter fell to $37 thousand from $380 thousand in the same period last year, primarily due to the conclusion of the company's 2003 research collaboration with Allergan Inc. (AGN) in March 2013. Analysts had a consensus revenue estimate of $310 thousand for the quarter.